Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the cloudy skies looming over the Pharmalot campus. After all, the squirrels are still gathering acorns and a warm breeze is emanating from the heating contraption. Moreover, this marks the middle of the week, which means we have managed to survive this far. And this calls for celebration, yes? So please join us as we hoist another cup of delicious stimulation. Remember, no prescription is required. Meanwhile, here are a few items of interest. Have a grand day and drop us a line if you hear something saucy.

The White House claimed that the drug pricing bill pushed by House Democrats would result in as many as 100 fewer drugs hitting the U.S. market over the next decade, CNBC says. Citing an analysis from the Council of Economic Advisers, the White House also argued the bill would lead to worse health outcomes and cost the U.S. economy $1 trillion per year over that time period. The report suggests far greater consequences than other estimates for both the pharmaceutical industry and American consumers if the bill is enacted.

Unlock this article by subscribing to STAT Plus. To get you started, enjoy 50% off your first 3 months!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy